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Abstract
Objective:  To  compare  the  biochemical  and  immunological  proﬁles  of  pediatric  patients  with
acute myeloid  leukemia  (AML)  with  healthy  children  and  adolescents.
Methods:  This  was  a  cross-sectional  study  in  which  21  therapy-naïve  patients  with  AML  were
compared with  a  group  of  24  healthy  individuals.  The  following  data  were  analyzed:  serum
proteins,  leucocytes  and  subgroups,  erythrocytes,  hematocrit,  hemoglobin,  platelets,  cytokines
in peripheral  blood  mononuclear  cells  cultures  under  spontaneous  and  BCG-  or  PHA-stimulated
conditions,  immunoglobulin  A,  and  erythrocytic  glutathione.  Statistical  analysis  was  performed
using SPSS  software,  considering  as  signiﬁcant  p-values  <  0.05.
Results:  Serum  albumin  levels  were  higher  (p  <  0.0001)  in  the  control  group,  as  well  as  all  the
parameters  related  to  red  blood  cells  (p  <  0.0001).  For  leucocytes  and  subgroups,  no  statistical
difference  was  found  between  the  AML  and  the  control  groups.  For  cytokines,  the  concentrations
were signiﬁcantly  higher  under  spontaneous  and  BCG-stimulated  conditions  for  TNF-,  IL-6,  IL-
10, and  IFN-  in  the  control  group.  Under  PHA-stimulated  conditions,  the  concentration  was
higher (p  =  0.002)  only  for  IL-6.  No  difference  was  found  between  the  two  groups  for  the  other
cytokines  and  for  IgA  in  the  saliva.  Erythrocytic  glutathione  was  higher  (p  <  0.0001)  in  AML
patients.
 Please cite this article as: Sanches FL, Nitsch TM, Vilela MM, Sgarbieri VC. Comparison of biochemical and immunological proﬁle of
ediatric patients with acute myeloid leukemia in relation to healthy individuals. J Pediatr (Rio J). 2015;91:478--84.
 Study conducted at Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
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Conclusions:  It  was  possible  to  characterize  the  biochemical  and  immunological  proﬁle  of  pedi-
atric patients  with  AML,  as  well  as  highlight  some  signiﬁcant  differences  in  these  parameters
when comparing  with  healthy  children  and  adolescents.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Comparac¸ão  do  perﬁl  bioquímico  e  imunológico  de  pacientes  pediátricos  com
leucemia  mieloide  aguda  e  de  indivíduos  saudáveis
Resumo
Objetivo:  Comparar  o  perﬁl  bioquímico  e  imunológico  de  pacientes  pediátricos  portadores  de
Leucemia Mieloide  Aguda  (LMA)  em  relac¸ão  a  um  grupo  de  crianc¸as  e  adolescentes  saudáveis.
Métodos: Estudo  transversal,  em  que  foram  avaliados  21  pacientes  com  LMA  virgens  de  ter-
apia e  um  grupo  de  24  indivíduos  saudáveis.  Foram  analisadas:  proteínas  séricas,  leucócitos  e
subgrupos,  eritrócitos,  hematócrito,  hemoglobina  e  plaquetas,  citocinas  em  cultura  de  células
mononucleares  do  sangue  periférico  sob  condic¸ão  espontânea  e  estimulada  por  BCG  ou  PHA,
imunoglobulina  A  e  glutationa  eritrocitária.  Análise  estatística  foi  realizada  através  do  software
SPSS considerando  p  <  0,05.
Resultados:  Albumina  sérica  foi  superior  (p  <  0,0001)  no  grupo  de  controle,  bem  como,  todos
os parâmetros  relacionados  com  os  glóbulos  vermelhos  (p  <  0,0001).  Para  os  leucócitos  e  sub-
grupos não  houve  diferenc¸a  estatística  entre  os  pacientes  com  LMA  e  o  grupo  controle.  As
concentrac¸ões foram  signiﬁcativamente  mais  elevadas  sob  condic¸ões  espontânea  e  estimulada
por BCG  para  as  citocinas  TNF-,  IL-6,  IL-10  e  IFN-  no  grupo  controle.  Sob  condic¸ão  estimulada
com PHA  a  concentrac¸ão  foi  superior  (p  =  0,002)  apenas  para  a  IL-6.  Não  houve  diferenc¸a  estatís-
tica para  as  demais  citocinas  e  para  IgA  salivar  entre  os  dois  grupos.  Glutationa  eritrocitária  foi
superior (p  <  0,0001)  nos  pacientes  LMA.
Conclusões:  Diante  do  exposto  foi  possível  caracterizar  o  perﬁl  bioquímico  e  imunológico  de
pacientes pediátricos  com  LMA,  bem  como,  evidenciar  diferenc¸as  signiﬁcativas  em  alguns
desses parâmetros  ao  se  comparar  os  indivíduos  doentes  e  o  grupo  de  crianc¸as  e  adolescentes
saudáveis.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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ticipation  of  a clinical  trial  of  nutritional  intervention.Introduction
Common  types  of  cancer  in  the  pediatric  age  range  include
leukemias,  particularly  acute  lymphocytic  leukemia  (ALL)
and  acute  myeloid  leukemia  (AML),  central  nervous  system
tumor,  lymphoma,  neuroblastoma,  Wilms  tumor,  osteosar-
coma,  and  Ewing’s  sarcoma.  Children  comprise  80%  of  ALL
cases,  and  only  10%  of  AML  cases.  An  increasing  prevalence
of  pediatric  cancer  has  been  observed  in  Brazil.1--3
Acute  leukemia  is  a  primary  neoplasia  of  the  bone
medulla,  characterized  by  a  heterogeneous  group  of  dis-
eases  in  which  there  is  a  substitution  of  normal  medullary
and  blood  elements  by  immature  cells  (blasts)  and  accumu-
lation  of  these  cells  in  other  tissues.4
According  to  Casciato,5 leukemic  cells  replicate  slower
than  the  corresponding  normal  cells.  Hematopoiesis  is
abnormal  even  before  the  proportion  of  cells  in  the
medulla  shows  a  perceptible  increase.  The  precursors  of
immature  leucocytes  exhibiting  malfunctioning  progres-
sively  substitute  the  bone  medulla  and  inﬁltrate  other
tissues.The  signs  and  symptoms  of  acute  leukemia  result  from  the
drop  of  blood  cells,  which  lead  to  anemia,  weakness,  general
discomfort,  paleness,  fatigue,  palpitation,  and  dyspnea  to
A
ixercise.  Fever  and  infections  may  occur  as  a  consequence
f  decreased  granulocytes.5,6
The  characterization  of  the  biochemical  and  immuno-
ogical  proﬁle  of  AML  patients  is  important  for  nutritional
nd  medical  interventions  and  following  normal  growth
nd  development  of  children  and  adolescents,  in  order
o  improve  the  immunological  response  and  tolerance  of
atients  to  treatment,  as  well  as  their  quality  of  life.
This  study  aimed  to  compare  the  biochemical  and
mmunological  proﬁles  of  pediatric  patients  with  AML  to
hose  of  healthy  individuals  matched  in  age.
ethods
opulation
he  studied  sample  comprised  patients  admitted  to  the  Cen-
ro  Infantil  Boldrini,  Campinas-SP,  Brazil,  for  treatment  of
eukemia,  immediately  after  the  diagnostic  of  AML,  and  par-The  inclusion  criteria  were:  a  conﬁrmed  diagnostic  for
ML;  treatment  naivety;  age  range  0--19  years;  having  an
nformed  consent  signed  by  the  patient  or  his/her  legal
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uardian,  after  being  informed  of  the  objectives  and  meth-
ds  employed  in  the  research  and  being  aware  of  the
rocedures  and  discomforts  to  which  participants  would  be
ubmitted,  being  free  to  accept  to  participate  or  not  without
onstraint.
The  study  also  included  a  control  group  of  healthy  chil-
ren  and  adolescents  in  the  same  age  range.  The  inclusion
riteria  for  this  group  were  individuals  without  any  pathol-
gy  nor  receiving  any  medication  at  the  time  of  selection  or
ample  collection  who  signed  an  informed  consent.
At  the  end  of  the  investigation,  21  patients  with  AML  had
een  evaluated:  11  females  and  10  males,  with  median  age
.83  years  (0.58--19.83).  The  control  group  was  composed  of
4  individuals  among  children  and  adolescents  distributed
etween  17  females  and  seven  males,  median  age  9.67
1.5--18.25)  years.  The  age  of  the  groups  was  not  signiﬁ-
antly  different  (p  =  0.351)  according  to  the  Mann--Whitney
est.
iochemical  and  immunological  evaluation
ample  collection
he  biological  samples  were  collected  from  the  patients  by
he  nursing  team  of  the  Instituto  Infantil  Boldrini,  where
ll  patients  were  diagnosed  and  recruited.  Between  15  and
0  mL  of  blood  were  collected,  carefully  avoiding  hemolysis.
Blood  from  healthy  individuals  was  collected  in  the  out-
atient  clinic  of  the  Centro  de  Investigac¸ão  em  Pediatria
CIPED)  by  the  nurse  in  charge.  For  saliva  collection,  a  plas-
ic  1  mL  sterile  and  rejectable  Pasteur  pipette  was  used.
he  participants  were  instructed  not  to  eat  or  drink  any-
hing  except  water  1  h  before  collection  and  to  practice  oral
ygiene  by  washing  the  mouth  with  pure  water.
osages  of  blood  serum  proteins
erum  prealbumin  fraction  was  determined  by  nephelom-
try  and  the  serum  albumin  by  the  colorimetric  reaction
ith  bromocresol  green  using  spectrophotometry.  The  anal-
ses  were  performed  in  the  biochemistry  laboratory  of  the
epartment  of  Clinical  Pathology  (DCP),  of  the  Hospital  das
línicas  of  the  Universidade  Estadual  de  Campinas  (UNI-
AMP).
emograms
he  hemograms  were  performed  at  the  Instituto  Infantil
oldrini  as  part  of  a  routine  in  the  clinical  treatment.  For
ealthy  individuals  (control  group),  the  hemograms  were
erformed  at  the  Laboratory  of  Clinical  Pathology  of  the
ospital  das  Clínicas  (UNICAMP).
educed  erythrocytic  glutathione
he  assay  followed  a  minor  modiﬁcation  of  the  method
escribed  by  Beutler,7 proposed  by  Penna8 200  L  of  periph-
ral  blood  EDTA  were  lysed  with  1.8  mL  of  distilled  water.
hen,  2  mL  of  1.67%  metaphosphoric  acid  solution  were
dded  and  the  mixture  was  ﬁltered.  4  mL  of  0.3  M  Na2HPO4
olution  were  added  to  1  mL  of  the  clear  ﬁltrate  and  read  at
12  nm  on  a  Bechman  spectrophotometer.  A  second  optical
ensity  reading  was  taken  after  the  addition  of  100  mL  of
ithiobisnitrobenzoic  acid  (DTNB)  solution  to  the  ﬁltrates.
esults  were  expressed  in  mg/dL.
T
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timuli  used  in  cultures
yophilized  BCG  (Moreau  Rio  de  Janeiro  vaccine  vials)  were
reshly  reconstituted  with  a  culture  medium  RPMI  1640
Sigma--Aldrich,  USA)  and  used  at  5  ×  105 UFC/mL.  Phy-
ohemagglutinin  (PHA,  Sigma--Aldrich,  USA)  was  used  a
on-speciﬁc  positive  control  at  7.5  g/mL,  and  medium
lone  was  used  as  a  negative  control.
ytokine  concentration  in  culture  supernatants  of
eripheral  blood  mononuclear  cells  (PBMC)
ytokine  concentration  was  measured  in  PBMC  cultures,  by
 modiﬁcation  of  the  protocol  of  Gaines  et  al.9 Fresh  PBMC
rom  patients  and  controls  were  isolated  by  density  gradi-
nt  centrifugation  over  Hystopaque® (Sigma--Aldrich,  USA),
ashed,  diluted  to  2  ×  106 cells/mL  in  RPMI  1640  medium
Sigma--Aldrich,  USA)  supplemented  with  10%  human  AB
erum  (Sigma--Aldrich,  USA),  1%  glutamine  (Sigma--Aldrich,
SA),  and  0.1%  gentamycin  and  stimulated  for  48  h  with
econstituted  BCG,  PHA,  or  medium  alone  at  37 ◦C  with  5%
O2 in  round-bottomed  96-well  tissue  culture  plates  (Nunc,
hermo  Fisher  Cientiﬁc,  USA).
Culture  supernatants  were  collected  and  stored  at  −80 ◦C
or  two-monoclonal  antibody  sandwich  enzyme  linked
mmunosorbent  assay  (ELISA).  Commercial  kits  (Duoset  RD
ystems,  United  States)  were  used  to  measure  interferon-
IFN-), tumor  necrosis  factor-  (TNF-), interleukin-6  (IL-
),  and  IL-10  concentration,  according  to  the  manufacturer’s
rotocol.  The  levels  of  the  transforming  growth  factor  beta
TGF-), and  IL-8  were  measured  in  blood  plasma.  All  sam-
les  were  measured  in  duplicates  and  the  results  were
xpressed  in  pg/mL.
mmunoglobulin  A  in  saliva
he  collected  saliva  was  centrifuged  at  1000  ×  g for  7  min
nd  then  stored  at  −80 ◦C  until  time  for  analysis;  the
esults  were  expressed  in  mg/mL.  The  concentration  of
mmunoglobulin  A  (IgA)  was  performed  by  nephelometry.
thical  aspects
ll  ethical  aspects  were  observed  as  recommended  for
iomedical  research  involving  human  beings,  according  to
he  National  Health  Council  resolution  No.  196  of  1996.  The
esearch  protocol  was  approved  by  the  National  Commit-
ee  for  Ethics  in  Research  (CONEP)  and  registered  under  No.
4097.
tatistical  analysis
ll  results  were  analyzed  using  SPSS® for  Windows  (Inc.
eleased  2007.  SPSS  for  Windows,  version  16.0,  USA).
escriptive  analysis  of  the  variables  were  presented  as
edian  (minimum  and  maximum  values).  The  comparison
f  biochemical  evaluation  among  patients  and  control  group
as  performed  using  the  Mann--Whitney  non-parametric  test
t  p  <  0.05.
esultshe  present  study  included  21  patients  with  AML  and  24
ealthy  subjects  paired  in  age,  with  no  statistical  differ-
nces.
Proﬁle  of  acute  myeloid  leukemia  patients  
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Figure  1  Erythrocytic  reduced  glutathione  concentration
(mg/dL)  of  acute  myeloid  leukemia  patients  and  healthy  sub-
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cjects (control)  in  the  same  age  range.  *Signiﬁcant  difference:
p <  0.05,  calculated  by  the  Mann--Whitney  Test.
Using  the  French  American  British  (FAB)  classiﬁcation,
nine  patients  were  classiﬁed  as  M5;  four,  as  M2;  one,  as
M1;  and  one,  as  M7.  Six  patients  did  not  have  the  sub-type
speciﬁed  in  their  medical  records.
Albumin  and  prealbumin  serum  proteins
Table  1  presents  the  comparative  results  of  serum  albumin
and  prealbumin  levels  for  AML  patients  and  controls.  It  was
observed  that  both  serum  albumin  and  prealbumin  were  sig-
niﬁcantly  higher  (p  <  0.0001)  in  the  healthy  individuals  when
compared  with  the  AML  patients.
Hematological  parameters
Table  2  presents  the  comparative  results  for  the  hema-
tological  parameters  between  AML  patients  and  healthy
individuals.
There  was  no  statistical  difference  in  the  median  levels
of  total  leucocytes  and  subgroups  (lymphocytes,  monocytes
and  granulocytes)  between  the  two  groups.  However,  the
higher  values  of  erythrocytes,  hematocrit,  hemoglobin  and
platelets  (p  <  0.0001)  in  the  control  group  when  compared
with  the  AML  patients  are  noteworthy.
Erythrocytic  reduced  glutathione  (GSH)
concentration
The  median  GSH  concentration  in  the  erythrocyte  of  AML
patients  was  signiﬁcantly  higher  (p  <  0.0001)  than  the  values
measured  in  healthy  subjects,  as  illustrated  in  Fig.  1.  GSH
concentration  was  82.88  (61.94--151.77)  mg/dL  in  the  AML
group,  compared  to  61.72  mg/dL  in  the  control  group.
Cytokine  concentration  in  supernatants  of  PBMC
cultures
Comparative  production  of  cytokines  was  determined  in
supernatants  of  peripheral  blood  mononuclear  cells  culture
t
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PBMC)  under  three  different  conditions  for  the  AML
nd  control  group:  spontaneous  (culture  medium  without
timulation);  culture  medium  plus  the  vaccine  BCG;  and
ulture  medium  plus  phytohemagglutinin  (PHA).  The  results,
xpressed  as  medium  values  and  the  spread  (min-max),  are
hown  in  Table  3.
Under  spontaneous  condition,  TNF- and  IFN- concen-
rations  were  signiﬁcantly  higher  in  the  AML  patients  than
n  healthy  subjects.  No  difference  was  found  between  the
wo  groups  for  IL-6  and  IL-10,  under  this  condition.
Under  BCG-stimulated  condition,  all  cytokines  concen-
rations  (TNF-, IL-6,  IL10,  IFN-) were  signiﬁcantly  higher
han  in  the  control  group.
In  the  presence  of  PHA,  only  IL-6  concentration  was  sig-
iﬁcantly  higher  (p  <  0.002)  in  the  control,  when  compared
ith  the  AML  group.  TNF- was  also  higher  the  control  than
n  the  AML  group;  however,  it  did  not  reach  statistical  sig-
iﬁcance.  No  difference  was  found  between  the  two  groups
or  IL-10  and  IFN- under  this  condition.
The  concentration  of  TGF- and  IL-8,  which  was  mea-
ured  in  the  blood  plasma  in  both  groups,  and  only  in
he  presence  of  BCG,  did  not  show  statistical  difference
etween  the  groups  (data  not  shown).
etermination  of  IgA  in  saliva
mmunoglobulin  A  (IgA)  was  determined  in  the  saliva  of  the
ubjects  in  both  groups  of  study.
The  concentration  of  IgA  was  6.5  (1--17.4)  mg/dL  for  the
ML  group  and  9.05  (1.8--25.1)  mg/dL  for  the  control  group,
howing  no  difference  (p  =  0.693)  between  the  groups.
iscussion
erum  proteins  have  been  used  as  a sensitive  indicator  for
ndernutrition.  However,  other  factors  not  related  to  nutri-
ional  condition  may  affect  the  level  of  serum  protein,  such
sstate  of  hydration,  reduction  of  hepatic  protein  synthesis,
ltered  capillary  permeability  due  to  infections  or  zinc  deﬁ-
iency  catabolism  in  periods  of  stress,  and  hypermetabolism
n  certain  neoplasias.10,11
The  present  albumin  (4.8  g/dL)  and  prealbumin
21.45  mg/dL)  results  in  the  control  group  were  statis-
ically  higher  (p  <  0.0001)  than  the  values  found  in  the  AML
atients.  These  results  reﬂect  differences  expected  in  the
utritional  state  of  healthy  children  and  adolescents  when
ompared  with  age-matched  AML  patients.
In  a  study  performed  on  226  adult  patients  with  cancer,
arín  Caro  et  al.12 found  that  32%  of  the  studied  popula-
ion  presented  serum  albumin  concentration  between  3.0
nd  3.5  g/dL  (mild  undernutrition),  demonstrating  a  nega-
ive  correlation  between  serum  protein  levels  and  feeding
roblem.
Severely  ill  patients  normally  present  metabolic  alter-
tions  in  carbohydrates,  lipids,  and  proteins.  Such  alter-
tions  result  from  increased  need  of  energy  and  protein
atabolism,  contributing  to  immunological  and  gastroin-
estinal  alterations.13
Regarding  the  hematological  parameters  (Table  2),  no
tatistical  differences  were  found  between  AML  patients  and
ealthy  subjects  for  leucocytes,  lymphocytes,  monocytes,
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Table  1  Levels  of  serum  albumin  and  prealbumin  in  acute  myeloid  leukemia  (AML)  patients  and  in  healthy  individuals  (control)
in the  same  age  range.
Serum  protein  AML
(n  =  21)
Control
(n  =  24)
Albumin Mediana 3.6  4.8
min--max (2.6--4.6)  (4.4--5.4)
pb <0.0001
Prealbumin Mediana 11.75  21.45
min--max (3.97--24.0)  (13.1--34.6)
pb <0.0001
a Median of minimum and maximum.
b p-value calculated by the Mann--Whitney test.
Table  2  Hematological  parameters  determined  in  pediatric  acute  myeloid  leukemia  (AML)  patients  and  in  healthy  individuals
(control) in  the  same  age  range.
Parameters  AML  (n  =  21)  Control  (n  =  24)  pa
Leucocytes  (cell  ×  109/L)  13.1b (1.1--494.0)  6.51b (1.79--15.11)  0.219
Lymphocytes  (cell  ×  109/L)  2.3  (0.6--58.4)  2.8  (1.83--8.64)  0.368
Monocytes (cell  ×  109/L)  1.3  (0.1--10.6)  0.45  (0.24--0.91)  0.308
Granulocytes  (cell  ×  109/L)  4.3  (0.1--48.6)  3.64  (1.91--5.57)  0.825
Erythrocytes  (cell  ×  1012/L)  2.55  (1.78--4.36)  4.82  (4.17--5.4)  <0.0001
Hematocrit (%)  23.4  (16.6--36.6)  40.7  (34.1--47.2)  <0.0001
Hemoglobin  (g/dL) 7.7  (5.6--12.5)  13.55  (11.1--15.5)  <0.0001
Plalelets (cell  ×  109/L)  38.0  (16--220)  307.0  (162--461)  <0.0001
a
h
m
a
t
(
aa p-value calculated by Mann--Whitney test.
b Median of minimum and maximum.
nd  granulocytes,  although  the  median  values  tended  to  be
igher  in  the  AML  group.  This  lack  of  statistical  signiﬁcance
ight  be  explained  as  a  function  of  two  factors:  (a)  the  rel-
tively  small  number  of  subjects  in  the  present  samples;  (b)
he  great  variability  normally  found  for  white  blood  cells
leucocytes)  in  patients  with  leukemia.5
c
(
s
Table  3  Cytokines  concentration  (pg/mL)  determined  in  superna
myeloid leukemia  (AML)  patients  and  healthy  subjects  (control)  in
Cytokines  Group  
Spontaneous  BCG
TNF- AML  40.491a (0.0--418.9)  831
Control 22.42  (0.0--316.7)  480
pb 0.011  <0.
IL-6 AML 455.641  (0.0--10,328.2)  480
Control 736.17  (19.8--5044.4)  28,
pb 0.197  <0.
IL-10 AML 0.0  (0.0--1796.8)  124
Control 0.0  (0.0--119.7)  615
pb 0.065  0.0
IFN- AML 23.17  (0.0--70.6)  98.
Control 0.0  (0.0--48.9)  676
pb 0.012  0.0
TNF, tumor necrosis factor; IL, interleukin; IFN, interferon.
a Median of minimum and maximum.
b Mann--Whitney test.Viana  et  al.14 conducted  a  study  on  83  children  with  AML
nd  also  found  a  wide  variation  in  the  number  of  leuco-
ytes/mL  of  blood.
In  the  present  study,  the  total  number  of  leucocytes
13.1  ×  109 cells/L)  for  the  AML  group  can  be  considered
lightly  above  normal  and  was  normal  for  the  control
tants  of  peripheral  blood  mononuclear  cells  cultures  of  acute
 the  same  age  range.
Conditions
 PHA
.47a (41.01--15,825.3)  683.17a (38.6--1977.2)
0.42  (1408.7--13,101.1)  986.61  (87.7--27,882.1)
0001  0.052
7.2  (41.0--31,186.7)  3010.4  (54.2--28,250)
961.67  (25,176.7--293,344.6)  9654.65  (1904--29,051.1)
0001  0.002
.54  (0.0--1783.05)  393.80  (63.8--1127.9)
.46  (118.6--2204.9)  627.52  (61.5--1465.2)
03  0.284
71  (0.0--1665)  150.23  (0.0--3913.8)
.77  (0.0--1935.3)  87.96  (0.0--630.5)
03  0.273
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tProﬁle  of  acute  myeloid  leukemia  patients  
(6.5  ×  109 cells/L),  since  the  reference  values  range  from  4.5
to  10.5  ×  109 cells/L.
Conversely,  erythrocytes,  hematocrit,  hemoglobin,  and
platelets  were  all  signiﬁcantly  higher  (p  <  0.0001)  in  the  con-
trol  group  when  compared  with  the  AML  group  (Table  2).
These  data  appear  to  explain  the  strong  tendency  for  anemia
in  AML  patients.
The  cell-mediated  immunity  against  tumors  can  increase
by  expression  of  cytokines  and  co-stimulators  in  tumoral
cells  and  by  treatment  of  tumors  carrying  individuals  with
cytokines,  which  stimulate  the  proliferation  and  differenti-
ation  of  T  lymphocytes  and  natural  killer  (NK)  cells.  IFN-
and  TNF- are  considered  efﬁcient  antitumoral  agents  in
animal  models,  but  their  use  in  patients  is  limited  due
to  serious  toxic  collateral  effects.  Growth  factors,  such
as  granulocytes--macrophages  colonies  stimulating  factor
(GM-CSF)  and  granulocytes  colonies  stimulating  factor  (G-
CSF)  are  used  in  cancer  treatment  protocols  to  decrease
the  periods  of  neutropenia  and  thrombocytopenia  after
chemotherapy  or  bone  medulla  autologous  transplant.15
One  study  compared  the  levels  of  pro-inﬂammatory
cytokines  in  adult  patients  with  cancer  with  a  group  of
healthy  subjects  (control).  It  was  found  that  the  blood  serum
levels  of  IL-1 and  TNF- were  higher  (p  <  0.0001)  in  patients
with  cancer,  when  compared  with  the  control  group.16
In  the  present  study,  the  spontaneous  production  of
TNF-  and  IFN- in  supernatants  of  PBMC  was  signiﬁcantly
higher  in  AML  patients,  suggesting  that  oxidative  stress  and
inﬂammation  are  involved  in  AML.  Conversely,  there  was  no
signiﬁcant  difference  between  groups  in  production  of  IL-6
and  IL-10,  which  act  as  regulatory  cytokines.
There  is  increasing  evidence  in  the  literature  that  the
ROS-induced  generation  of  oxidative  stress  plays  a  role  in
leukemia.  A  strong  association  between  oxidative  stress  and
the  incidence  of  disease  relapse  was  demonstrated  by  Zhou
et  al.17 These  investigators  showed  that  the  activities  of
adenosine  deaminase  and  xanthine  oxidase  were  higher  in
AML  relapse  condition,  whereas  those  of  glutathione  perox-
idase,  monoamine  oxidase,  superoxide  dismutase,  and  the
total  antioxidant  capacity  (T-AOC)  were  lower  in  the  pri-
mary  condition  than  in  controls.  According  to  these  authors,
oxidative  stress  is  a  crucial  feature  of  AML  and  probably
affects  its  development  and  relapses.
In  the  present  study  (Table  3),  all  cytokines  investigated
showed  signiﬁcantly  higher  concentrations  in  the  control
group  when  compared  with  the  AML  group  in  the  presence
of  BCG  vaccine,  a  speciﬁc  antigenic  factor,  which  suggests
a  lower  capacity  of  AML  patients  to  positively  react  to  anti-
gens.  Conversely,  in  the  presence  of  PHA,  a  non-speciﬁc
mitogen  stimulator,  only  IL-6  showed  signiﬁcantly  higher
concentration  in  the  control  (p  <  0.002)  when  compared  with
the  AML  group.  TNF-, IL-10,  and  IFN- did  not  show  differ-
ence  between  the  two  groups.
Adequate  concentration  of  glutathione  is  necessary  for
normal  cell  proliferation  including  lymphocytes  and  epithe-
lial  cells  in  the  intestine.18 Glutathione  (GSH)  is  also
essential  for  the  activation  of  T  lymphocytes  and  poly-
morphonuclear  leucocytes  and  also  for  the  production  of
cytokines;  therefore  it  is  indispensable  for  the  expression
of  the  immune  response  in  situations  of  immunological
challenges.19 The  authors  cited  above  mentioned  that  the
f
o483
ellular  concentrations  of  GSH  are  drastically  reduced
n  situations  such  as  protein  undernutrition  and  oxida-
ive  stress,  and  in  various  pathological  conditions,  such
s  protein-energy  undernutrition,  acquired  immunological
eﬁciency  (AIDS),  and  advanced  neoplasias.
A  study  by  Russo  et  al.20 demonstrated  that  the  levels
f  GSH  in  cancer  cells  may  be  several  folds  higher  than  in
orresponding  normal  cells.  According  to  Engin,21 the  lev-
ls  of  erythrocytic  glutathione  were  31%  higher  in  patients
ith  localized  carcinoma  and  78%  higher  in  patients  with
etastatic  cancer  compared  with  healthy  controls.  These
esults  may  reﬂect  the  high  levels  of  GSH  in  tumors  and  also
hat  these  high  levels  may  be  associated  with  resistance  of
umoral  cells  to  chemotherapeutic  treatment.
The  results  of  the  present  are  in  accordance  with  those  of
usso  et  al.20 and  Engin,21 revealing  a  higher  concentration
f  GSH  in  the  AML  patients  (p  <  0.0001)  when  compared  with
he  healthy  subject  group  (control),  as  illustrated  in  Fig.  1.
Recent  published  study22 indicated  that  CD34+ AML  cells
ave  elevated  expression  of  multiple  glutathione  pathway
egulatory  proteins,  presumably  as  a  mechanism  to  com-
ensate  to  increased  oxidative  stress  in  leukemic  cells.
onsistent  with  this  observation  CD34+ AML  cells  have  lower
evels  of  reduced  (GSH)  and  increased  levels  of  oxidized
GSSG)  glutathione.  These  ﬁndings  suggest  the  intrinsic  bal-
nce  and  homeostasis  and  the  GSH  to  GSSG  ration  is  altered
aberrant)  in  the  CD34+ AML  cells.
The  above  cited  authors  propose  that  the  decreased
SH  level  is  due  to  higher  consumption  of  GSH  in  sev-
ral  processes  required  for  cancer  cell  survival  including:
1)  reduction  of  reactive  oxygen  species,  such  as  H2O2;  (2)
roper  S-glutathionylation  of  the  proteome  in  response  to
xidative  stress;  and  (3)  detoxiﬁcation  of  increased  produc-
ion  of  lipid  peroxides.
These  same  authors  also  presented  new  agents  such  as
arthenolide  (PTL)  and  piperlongumine  (PLM)  having  a  dra-
atic  inhibitory  effect  on  the  leukemic  GSH  system,  whereas
nly  a  limited  and  transient  perturbation  in  normal  cells.
he  same  group  of  researchers  had  previously  shown,23
he  PTL  effectively  eradicated  AML  stem  and  progenitor
ells  that  are  typically  resistant/refractory  to  conventional
hemotherapy.
Secretory  salivary  immunoglobulin  A  (sIgA)  is  an  impor-
ant  parameter  for  evaluating  the  immunological  status  of
he  gastrointestinal  mucosa,  with  the  advantage  of  using
oninvasive  procedure  and  essentially  without  discomfort
o  the  patient.  It  is  considered  the  most  important  humoral
ediator  for  the  mucosa  immunity,  assisting  in  a  variety  of
rotective  mechanisms.  It  presents  higher  resistance  to  pro-
eolytic  degradation  than  any  other  class  of  immunoglobulin
nd  can  be  found  in  the  entire  digestive  and  respiratory
racts,  impeding  the  absorption  of  a  large  quantity  of
ntigens.24,25
According  to  Souza  et  al.,26 in  patients  with  cancer,  the
ynthesis  of  antibodies  may  be  decreased  or  exacerbated
epending  on  the  immunological  mechanisms  involved  in
he  proliferation  of  tumoral  cells,  determining  an  eleva-
ion  or  reduction  in  the  concentrations  of  immunoglobulin
ractions.
In  the  present  study,  no  statistical  difference  was
bserved  in  the  concentration  of  salivary  IgA  (p  =  0.693)
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etween  the  AML  patients  and  the  healthy  controls,  in  spite
f  detecting  higher  levels  in  the  patients.
In  the  comparison  of  pediatric  patients  with  AML  with
ormal  subjects  matched  for  age  some  conclusions  could
e  drawn:  a)  the  AML  group  presented  signiﬁcantly  lower
oncentrations  of  serum  albumin  and  prealbumin,  suggest-
ng  imminent  danger  of  protein  undernutrition:  b)  the  AML
atients  showed  lower  values  (p  <  0.0001)  for  all  red  blood
ells  parameters,  suggesting  a  state  of  anemia  in  these
atients;  (c)  the  statistic  lower  production  of  cytokines
f  AML  group  under  spontaneous  and  BCG-stimulated  con-
itions  appears  to  indicate  a  drop  in  the  immunological
esponse  of  patients  compared  to  the  normal  subjects;  (d)
he  signiﬁcantly  higher  GSH  concentration  in  the  erythro-
ytes  of  AML  patients,  compared  to  controls,  may  reﬂect  the
berrant  glutathione  metabolism  and  homeostasis  described
n  the  reference.22
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